Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
雄激素抑制与选择性淋巴结和剂量递增相结合。
批准号：
463259
负责人：
Loblaw Douglas Andrew B
金额：
$326.02万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-03-01 至 2031-09-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
External beam radiotherapy (EBRT), brachytherapy boost and androgen deprivation therapy (ADT) is the evidence-based standard of care for unfavourable risk (high-tier intermediate or high risk) prostate cancer.
Stereotactic body radiotherapy (SBRT) is a
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
